Outcomes with revascularisation versus conservative management of participants with 3-vessel coronary artery disease in the ISCHEMIA trial
EuroIntervention · 2024
DOI: 10.4244/eij-d-24-00240 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift EuroIntervention, 2024. Verfasst von Sripal Bangalore und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA. Hauptthemen laut MEDLINE: Coronary Artery Disease, Percutaneous Coronary Intervention, Coronary Artery Bypass, Conservative Treatment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
BACKGROUND: Whether revascularisation (REV) improves outcomes in patients with three-vessel coronary artery disease (3V-CAD) is uncertain. AIMS: Our objective was to evaluate outcomes with REV (percutaneous coronary intervention [PCI] or coronary artery bypass graft surgery [CABG]) versus medical therapy in patients with 3V-CAD. METHODS: ISCHEMIA participants with 3V-CAD on coronary computed tomography angiography without prior CABG were included. Outcomes following initial invasive management (INV) with REV (PCI or CABG) versus initial conservative management (CON) with medical therapy alone were evaluated. Regression modelling was used to estimate the outcomes if all participants were to undergo prompt REV versus those assigned to CON. Outcomes were cardiovascular (CV) death/myocardial infarction (MI), death, CV death, and quality of life. Bayesian posterior probability for benefit (Pr [benefit]) for 1 percentage point lower 4-year rates with REV versus CON were evaluated. RESULTS: Among 1,236 participants with 3V-CAD (612 INV/624 CON), REV was associated with lower 4-year CV death/MI (adjusted 4-year difference: -4.4, 95% credible interval [CrI] -8.7 to -0.3 percentage points, Pr [benefit]=94.8%) when compared with CON, with similar results for PCI versus CON (-5.8, 95% CrI: -10.8 to -0.5 percentage points, Pr [benefit]=96.4%) and CABG versus CON (-3.7, 95% CrI: -8.8 to 1.5 percentage points, Pr [benefit]=84.7%). Adjusted 4-year REV versus CON differences were as follows: death -1.2 (95% CrI: -4.7 to 2.2) percentage points, CV death -2.3 (95% CrI: -5.5 to 0.8) percentage points, with similar results for PCI and for CABG. The Pr (benefit) for death with REV (PCI or CABG) versus CON was 49-63%. The adjusted 12-month Seattle Angina Questionnaire-7 summary score differences favoured REV: REV versus CON 4.6 (95% CrI: 2.7-6.4) percentage points; PCI versus CON 3.6 (95% CrI: 1.2-5.8) percentage points and CABG versus CON 4.3 (95% CrI: 1.5-6.9) percentage points with high Pr (benefit). CONCLUSIONS: In participants with 3V-CAD, REV (either PCI or CABG) was associated with a lower 4-year CV death/MI rate and improved quality of life, with similar results for PCI versus CON and CABG versus CON. The differences in all-cause mortality between REV and CON were small with wide confidence intervals. (ClinicalTrials.gov: NCT01471522).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medicine, New York University Grossman School of Medicine, New York, NY, USA.
- Duke Clinical Research Institute, Durham, NC, USA.
- Department of Medicine, Stanford University, Stanford, CA, USA.
- Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, MO, USA.
- The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
- Te Whatu Ora Health New Zealand, Te Toka Tumai, Green Lane Cardiovascular Services and University of Auckland, Auckland, New Zealand.
Förderung
- NCATS NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Bangalore, S., Rhodes, G., Maron, D. J., Anthopolos, R., O'Brien, S. M., Jones, P. G., Mark, D. B., Reynolds, H. R., Spertus, J. A., Stone, G. W., White, H. D., Xu, Y., Fremes, S. E., Hochman, J. S., & Ischemia Research Group, O. B. O. T. (2024). Outcomes with revascularisation versus conservative management of participants with 3-vessel coronary artery disease in the ISCHEMIA trial. EuroIntervention. https://doi.org/10.4244/eij-d-24-00240
Vancouver
Bangalore S, Rhodes G, Maron DJ, Anthopolos R, O'Brien SM, Jones PG, et al. Outcomes with revascularisation versus conservative management of participants with 3-vessel coronary artery disease in the ISCHEMIA trial. EuroIntervention. 2024. doi:10.4244/eij-d-24-00240
BibTeX
@article{Bangalore2024,
author = {Bangalore, Sripal and Rhodes, Grace and Maron, David J and Anthopolos, Rebecca and O'Brien, Sean M and Jones, Philip G and Mark, Daniel B and Reynolds, Harmony R and Spertus, John A and Stone, Gregg W and White, Harvey D and Xu, Yifan and Fremes, Stephen E and Hochman, Judith S and Ischemia Research Group, On Behalf Of The},
title = {Outcomes with revascularisation versus conservative management of participants with 3-vessel coronary artery disease in the ISCHEMIA trial},
journal = {EuroIntervention},
year = {2024},
doi = {10.4244/eij-d-24-00240}
}
EUVIMED